EUVIMEDΑνακαλύψτε το EUVIMED
Qualitative StudieStudienprotokollOpen access · CC BY 4.0

Aripiprazole/Sertraline Combination: Clinical and Cost‐Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)—Protocol for a Nested Qualitative Study

Isobel Hoppe iD, Stuart Watson iD, Caroline Kemp, Fiona Turnbull, Firoza Davies, John Gibson iD, Lumbini Azim iD, Lauren Wall, Niraj Ahuja iD, Sarah Al-Ashmori iD, Sally Keys, Thomas Kabir iD and 1 more

Health Expectations · 2024

DOI: 10.1111/hex.70018 ↗

At a glance

Qualitative Studie in Health Expectations, 2024. Written by Isobel Hoppe and 12 co-authors. Institution: School of Medicine, Keele University, Newcastle, UK. Major MEDLINE topics: Bipolar Disorder, Aripiprazole, Quetiapine Fumarate, Qualitative Research. Cited 1 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: This ASCEnD trial is funded by the National Institute for Health and Care Research (NIHR) (Project Reference Number NIHR132773). CC-G is part-funded by WM ARC..

ΠερίληψηSubjectsΒιβλιογραφικά στοιχείαCiteRelated studies

Abstract (original language)

Introduction

Bipolar disorder is a recurrent mental health disorder with a prevalence rate of 1.4%. On average, there can be a delay of 9.5 years from the initial presentation of symptoms to a confirmed diagnosis. Individuals living with bipolar disorder have a reduced life expectancy. There is limited evidence regarding the effectiveness of antidepressants in treating bipolar disorder. The ASCEnD clinical trial will test the clinical and cost‐effectiveness of the aripiprazole/sertraline combination in comparison with quetiapine for the treatment of bipolar depression (individuals who suffer from depressive episodes in bipolar disorder) and will include a nested qualitative study.

Methods

The qualitative study will use semi‐structured interviews to explore pilot trial participants' and clinicians' perspectives on recruitment procedures, the acceptability of the intervention, the management of bipolar disorder and attitudes to medication combinations.

Conclusion

Findings will inform recruitment strategies and optimise training for the participating sites in the ASCEnD full trial. They will also help to illuminate the lived experience of people with bipolar disorder and the clinicians who work with people with bipolar disorder. The discussion will explore perspectives on the delay in diagnosis, having a diagnosis, the impact of living with bipolar disorder and attitudes to treatment, including drug combinations. Patient or Public Contribution A Lived Experience Advisory Panel (LEAP) has been convened with the support of the McPin Foundation, which will contribute to the ASCEnD trial and its nested qualitative study to provide input on the design and delivery of the trial and qualitative study, analysis of qualitative data and dissemination of findings.

Subjects

MeSH terms (MEDLINE)

Bipolar DisorderAripiprazoleQuetiapine FumarateQualitative ResearchCost-Benefit AnalysisAntipsychotic AgentsHumansAntidepressive AgentsInterviews as TopicDrug Therapy, CombinationFemaleMaleAdult

Author keywords

bipolar depressionbipolar disorderclinical trialmental healthnested qualitative studypatient and public involvement

Substances

AripiprazoleQuetiapine FumarateAntipsychotic AgentsAntidepressive Agents

Authors and institutions

  • School of Medicine, Keele University, Newcastle, UK.
  • Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Cumbria, Northumberland, Tyne and Wear NHS Trust, Newcastle upon Tyne, UK.
  • McPin Foundation, London, UK.
  • Cumbria, Northumberland, Tyne and Wear NHS Trust, Newcastle University, Newcastle upon Tyne, UK.
  • Regional Affective Disorders Service, Cumbria, Northumberland, Tyne and Wear NHS Trust, Newcastle upon Tyne, UK.

ORCID profiles: Isobel Hoppe, Stuart Watson, John Gibson, Lumbini Azim, Niraj Ahuja, Sarah Al-Ashmori, Thomas Kabir, Carolyn A Chew-Graham

Funding

  • This ASCEnD trial is funded by the National Institute for Health and Care Research (NIHR) (Project Reference Number NIHR132773). CC-G is part-funded by WM ARC.

Cite

APA

Hoppe, I., Watson, S., Kemp, C., Turnbull, F., Davies, F., Gibson, J., Azim, L., Wall, L., Ahuja, N., Al-Ashmori, S., Keys, S., Kabir, T., & Chew-Graham, C. A. (2024). Aripiprazole/Sertraline Combination: Clinical and Cost‐Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)—Protocol for a Nested Qualitative Study. Health Expectations. https://doi.org/10.1111/hex.70018

Vancouver

Hoppe I, Watson S, Kemp C, Turnbull F, Davies F, Gibson J, et al. Aripiprazole/Sertraline Combination: Clinical and Cost‐Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)—Protocol for a Nested Qualitative Study. Health Expectations. 2024. doi:10.1111/hex.70018

BibTeX
@article{Hoppe2024,
  author = {Hoppe, Isobel and Watson, Stuart and Kemp, Caroline and Turnbull, Fiona and Davies, Firoza and Gibson, John and Azim, Lumbini and Wall, Lauren and Ahuja, Niraj and Al-Ashmori, Sarah and Keys, Sally and Kabir, Thomas and Chew-Graham, Carolyn A},
  title = {Aripiprazole/Sertraline Combination: Clinical and Cost‐Effectiveness in Comparison With Quetiapine for the Treatment of Bipolar Depression (ASCEnD Trial)—Protocol for a Nested Qualitative Study},
  journal = {Health Expectations},
  year = {2024},
  doi = {10.1111/hex.70018}
}
Start for free →